.jpeg)
As of this writing, the only commercially available product Moderna has is its COVID-19 vaccine. While this revenue stream has slowed drastically, it should continue into the foreseeable future. The company will how to write rfp for software develop updated versions as the virus continues to change over time.
About MarketBeat
That low (just $1.05 or 3% above the stock’s 52-week low) followed Wolfe Research initiating coverage of Moderna with analyst Alexandria Hammond rating the stock an “Underperform” and setting a 12-month price target of $40. Moderna’s strategy jolted investors enough to send shares diving 14% over the two days following the announcement, to $68.28 on September 13 from $79.51. That’s because the company pushed back by two years, from 2026 to 2028, its plans to break even on an operating cash cost basis—which excludes stock-based compensation, depreciation, and amortization expense—with $6 billion in revenue. Expanding beyond COVID is going to be key to Moderna stock being a good long-term investment. The company does have products in its pipeline that could be blockbusters, including its RSV vaccine (peak sales of up to $2.1 billion) and its vaccine for the cytomegalovirus (potentially $5 billion at its peak).
.jpeg)
Jefferies says market nears short term “peak RFK negativity”, Vaccine makers up
Moderna head of investor relations Lavina Talukdar said at the Jefferies London Healthcare Conference on Thursday that the Cambridge, Mass.-based company sees 2028 as the year by which its revenue can sustain its business. But with Moderna scaling back its COVID operations and demand for the shots likely being lower in the future, I would be surprised if this were still a major source of revenue for the business in five years. If it is still relying on COVID revenue, that could be a bad sign, indicating that the company hasn’t come out with more promising products along the way. The launch of the RSV vaccine is already being planned for by the company, which believes there is a $10 billion global market for this drug.
Finally, HSBC raised shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective on the stock in a report on Monday, November 18th. Three equities research analysts have rated the stock android vs ios app development with a sell rating, thirteen have given a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $83.26. The biotech company had seen both sales and its stock price plummet as demand for its coronavirus vaccine waned, but seemed to be on the road to recovery. It won approval for its new respiratory syncytial virus (RSV) vaccine, reported positive data from trials of late-stage candidates, and even saw its shares climb about 20% in the first half of the year. A number of other institutional investors have also modified their holdings of the stock.
Analyst Forecast
It has the funds necessary to reach its break-even goal without having to raise additional equity, a major plus. As part of this, Moderna is cutting its R&D investment for the period of 2025 through 2028 by 20%, to $16 billion. This doesn’t mean the company will neglect its high-priority programs, though — it will actually increase its investment in oncology, for example, while slowing investment in other areas like rare-disease therapeutics. EMERYVILLE, Calif.–(BUSINESS WIRE)–CRDMO capabilities are tailored for a full range of mRNA applications, including small-scale quantities for personalized cancer vaccines (PCVs).
In the months leading up to the combination, the stock yo-yoed from $6.84 on August 8, peaking at $7.84 on November 11 before retreating. Moderna CEO Stéphane Bancel and president Stephen Hoge (joined at the event by Lavina Talukdar, the company’s senior vice president and head of investor relations) based their optimism in part on the historic administrative relationship between HHS and its secretaries. Talukdar downplayed the nomination of vaccine skeptic Robert F. Kennedy Jr. to head the Department of Health and Human Services (HHS) by President-elect Donald Trump, which had hammered pharma companies like Moderna, Pfizer (PFE) and Eli Lilly (LLY) last Friday.
Mizuho’s Jared Holz on what Trump’s FDA pick means for biotech innovation
- They set a “market perform” rating and a $55.00 price target for the company.
- In 2023, other companies sold approximately $2.3 billion in RSV vaccines, demonstrating the opportunity Moderna has in this market.
- Finally, Swiss National Bank raised its stake in Moderna by 0.3% during the third quarter.
- As of this writing, the only commercially available product Moderna has is its COVID-19 vaccine.
- However, Moderna is developing a robust pipeline that could propel the company for the foreseeable future.
(And buying the stock now, on the dip, could be a smart move too.) Moderna has five respiratory vaccines that have generated positive phase 3 data, and five non-respiratory candidates involved in pivotal studies. So there’s reason to be optimistic about the company’s product approval forecasts, and therefore its revenue potential down the road. Founded in 1993, xtrade forex The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, personal finance education, top-rated podcasts, and non-profit The Motley Fool Foundation. It expects its respiratory vaccines to be profitable this year and in the future.
In 2023, other companies sold approximately $2.3 billion in RSV vaccines, demonstrating the opportunity Moderna has in this market. However, Moderna is developing a robust pipeline that could propel the company for the foreseeable future. Is that pipeline strong enough to warrant buying the stock now, or should investors sit on the sidelines and wait? Before the COVID-19 pandemic, most investors likely hadn’t heard of Moderna (MRNA 3.19%).
Please bear with us as we address this and restore your personalized lists. The company also deprioritized a second program for a fourth candidate, REC-4881, in advanced AXIN1/APC-mutant cancers. At HHS, Kennedy would oversee agencies that include the FDA—for which Trump said Friday he plans to nominate Marty Makary, MD, as commissioner—and the U.S.